Lyrica in the Supreme Court: broader lessons for pharmaceuticals
There was much excitement surrounding the Supreme Court’s judgment in November on Pfizer’s second medical use patent for Pregabalin for pain (Pfizer’s blockbuster Lyrica drug).
Now that the dust has settled, this event on 15 January, will look into the broader implications for the pharmaceutical sector and the competitive framework for drugs with both patented and unpatented uses.
David Rosenberg, Vice President IP Policy at GlaxoSmithKline and Darren Smyth, UK and European Patent Attorney and head of EIP’s chemistry practice group EIP Elements will be speaking.
Sophie Lawrance will be attending.
For more information and to register, please see the CLA website.